Immunocore Open menu Autoimmune and Inflammation Diseases Aiming to transform the treatment of debilitating conditions Home / Our therapy areas / Autoimmune and Inflammation Diseases At Immunocore, we are expanding our bi-specific TCR- technology research platform to develop treatments for autoimmune diseases. Autoimmune diseases are often chronic and debilitating and constitute an area of high unmet clinical need. We believe that organ-specific immune suppression, rather than systemic immunosuppression, may benefit patients by avoiding adverse events due to systemic immunosuppression. We are now advancing our ImmTAAI drug portfolio with the aim to selectively suppress inflammation in any organ or tissue. Current autoimmune therapies Goal of ImmTAAI platform development Targeted ImmTAAI inhibits T cells (and protects tissue from autoimmune attack) ImmTAAI® (Immune Modulating Monoclonal TCRs Against Autoimmune Disease) bispecific molecules are designed with an organ-specific TCR fused to an immune suppressive effector function. Data in preclinical models suggest that target cell-bound ImmTAAI molecules can potently inhibit autoreactive T cells without risk of systemic immune suppression. IN THIS SECTION Our Therapy Areas Oncology Infectious Diseases Immunocore About us Our science Our therapy areas For patients Investors/Media Careers Contact us Privacy and Social Media Guidelines Cookies Payments and Disclosures Clinical trials Gender Pay Report ©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the Cookie notice I Accept